CRSP Stock Analysis: Crispr Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 4.762m USD | 12M Return: -26.5% | CH0334081137 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 74.9M
Qual. Beats: 0
Rev. Trend: -89.3%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 9.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
CRISPR Therapeutics AG (NASDAQ: CRSP) is a Swiss-based biotechnology company developing gene-editing medicines using its proprietary CRISPR/Cas9 platform, which enables precise modification of genomic DNA sequences. The company was founded in 2013 and listed on the U.S. market in October 2016, and its mid-cap market value reflects its position as a clinical-stage player in the gene-editing space. It has a broad pipeline spanning hemoglobinopathies, CAR T cell therapies, in vivo gene editing, and type 1 diabetes, with its lead product, CASGEVY, being an ex vivo gene-edited cell therapy approved for transfusion-dependent beta-thalassemia and severe sickle cell disease. Strategic collaboration with Vertex Pharmaceuticals supports CASGEVYs commercialization and broader development efforts, illustrating the partnership-driven model common in biotech where large pharma helps fund and distribute advanced therapies.
- CASGEVY launch uptake drives sickle cell and beta-thalassemia revenue ramp
- Vertex partnership milestone payments expand operating runway
- In vivo gene editing pipeline readouts validate platform expansion potential
| Net Income: -451.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.14 > 0.02 and ΔFCF/TA 4.25 > 1.0 |
| NWC/Revenue: 16.7k% < 20% (prev 4.36k%; Δ 12.4k% < -1%) |
| CFO/TA -0.14 > 3% & CFO -369.6m > Net Income -451.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 17.85 > 1.5 & < 3 |
| Outstanding Shares: last quarter (96.5m) vs 12m ago 10.85% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.57% > 50% (prev 1.84%; Δ -1.27% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.84 (Total Current Assets 2.37b - Total Current Liabilities 132.9m) / Total Assets 2.65b |
| B: -0.82 (Retained Earnings -2.16b / Total Assets 2.65b) |
| C: -0.20 (EBIT TTM -472.7m / Avg Total Assets 2.34b) |
| D: 1.93 (Book Value of Equity 1.75b / Total Liabilities 904.2m) |
| Altman-Z'' = 3.55 = A |
As of October 25, 2026, the stock is trading at USD 49.39 with a total of 1,924,763 shares traded. Over the past week, the price has changed by +0.28%, over one month by -11.42%, over three months by +3.91% and over the past year by -26.51%.
Current recommended Stop Loss: 46.30 (which is 6.3% or 1.2 ATR below the current price).
Crispr Therapeutics has received a consensus analysts rating of 3.91. Therefore, it is recommended to buy CRSP.
- StrongBuy: 8
- Buy: 5
- Hold: 10
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 85.6 | 73.4% |
P/E Forward = 23.3645
P/S = 355.5939
P/B = 3.087
P/EG = -0.2142
Revenue TTM = 13.4m USD
EBIT TTM = -472.7m USD
EBITDA TTM = -454.0m USD
Long Term Debt = 586.2m USD (from longTermDebt, last quarter)
Short Term Debt = 18.6m USD (from shortTermDebt, last quarter)
Debt = 981.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 197.6m
Net Debt = -1.38b USD (calculated: Debt 981.3m - CCE 2.36b)
Enterprise Value = 3.38b USD (4.76b + Debt 981.3m - CCE 2.36b)
Interest Coverage Ratio = unknown (Ebit TTM -472.7m / Interest Expense TTM 0.0)
EV/FCF = -9.17x (Enterprise Value 3.38b / FCF TTM -368.3m)
FCF Yield = -10.90% (FCF TTM -368.3m / Enterprise Value 3.38b)
FCF Margin = -2.75k% (FCF TTM -368.3m / Revenue TTM 13.4m)
Net Margin = -3.37k% (Net Income TTM -451.1m / Revenue TTM 13.4m)
Gross Margin = unknown ((Revenue TTM 13.4m - Cost of Revenue TTM 218.9m) / Revenue TTM)
Tobins Q-Ratio = 1.27 (Enterprise Value 3.38b / Total Assets 2.65b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 981.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -373.4m (EBIT -472.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 16.45 (Total Current Assets 2.37b / Total Current Liabilities 144.2m)
Debt / Equity = 0.56 (Debt 981.3m / totalStockholderEquity, last quarter 1.75b)
Debt / EBITDA = 3.05 (negative EBITDA) (Net Debt -1.38b / EBITDA -454.0m)
Debt / FCF = 3.75 (negative FCF - burning cash) (Net Debt -1.38b / FCF TTM -368.3m)
Total Stockholder Equity = 1.85b (last 4 quarters mean from totalStockholderEquity)
RoA = -19.28% (Net Income -451.1m / Total Assets 2.65b)
RoE = -24.39% (Net Income TTM -451.1m / Total Stockholder Equity 1.85b)
RoCE = -19.41% (EBIT -472.7m / Capital Employed (Equity 1.85b + L.T.Debt 586.2m))
RoIC = -14.73% (negative operating profit) (NOPAT -373.4m / Invested Capital 2.54b)
WACC = 9.36% (E(4.76b)/V(5.74b) * Re(11.29%) + D(981.3m)/V(5.74b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.29% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.28 | Cagr: 7.63%
[DCF] Fair Price = unknown (Cash Flow -368.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.48 | # QB: 0
Revenue Correlation: -89.33 | Revenue CAGR: -79.21% | SUE: 0.29 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-1.06 | Chg30d=-0.89% | Revisions=-25% | Analysts=17
EPS current Year (2026-12-31): EPS=-4.45 | Chg30d=-0.01% | Revisions=-25% | GrowthEPS=+31.3% | GrowthRev=+1052.1%
EPS next Year (2027-12-31): EPS=-3.55 | Chg30d=-1.62% | Revisions=-25% | GrowthEPS=+20.1% | GrowthRev=+273.9%
[Analyst] Revisions Ratio: -50% (up=0, down=3)